Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Payables (2019 - 2025)

Historic Payables for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • C4 Therapeutics' Payables fell 1136.97% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1136.97%. This contributed to the annual value of $1.3 million for FY2024, which is 816.04% down from last year.
  • Latest data reveals that C4 Therapeutics reported Payables of $1.3 million as of Q3 2025, which was down 1136.97% from $2.2 million recorded in Q2 2025.
  • C4 Therapeutics' Payables' 5-year high stood at $4.5 million during Q4 2021, with a 5-year trough of $683000.0 in Q1 2025.
  • Moreover, its 5-year median value for Payables was $1.6 million (2024), whereas its average is $2.3 million.
  • In the last 5 years, C4 Therapeutics' Payables tumbled by 7399.02% in 2022 and then soared by 14271.63% in 2025.
  • C4 Therapeutics' Payables (Quarter) stood at $4.5 million in 2021, then tumbled by 73.99% to $1.2 million in 2022, then increased by 23.38% to $1.4 million in 2023, then decreased by 8.16% to $1.3 million in 2024, then rose by 0.38% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $683000.0 during Q1 2025.